CVS Health Stock Slides on Dual FTC and DOJ Settlements

Shares of CVS Health Corp. fell in pre-market trading after the company disclosed two significant legal and regulatory settlements. The agreements include a sweeping deal with the Federal Trade Commission (FTC) that will reshape the business practices of its Caremark pharmacy benefit manager (PBM) and a separate, nine-figure settlement with the Department of Justice (DOJ).

FTC Settlement Alters PBM Model

CVS's Caremark unit finalized a settlement with the FTC on Tuesday evening that resolves all litigation and investigations tied to its PBM and pharmacy businesses, according to a report from Investing.com. The agreement requires Caremark to implement structural changes that are prompting investors to reassess the unit's future profitability.

Key terms of the FTC consent order include:

• Moving away from rebate guarantees and spread pricing, two core components of the traditional PBM revenue model.
• Aligning member cost-sharing directly with the net cost of drugs after rebates are applied.
• Counting consumer purchases made via the TrumpRx program toward their health plan deductibles.

These changes are part of a broader FTC campaign to reform PBM practices across the healthcare industry. Competitors, including Cigna, have faced similar regulatory actions, signaling a shift in the competitive landscape for managed care.

Omnicare Case Adds Financial Pressure

Ad

Adding to investor concerns, CVS and its bankrupt subsidiary Omnicare reached a $440 million settlement with the Department of Justice. The agreement resolves a False Claims Act judgment related to millions of fraudulent prescription claims filed between 2010 and 2018.

Under the terms, CVS is required to make an initial payment of $130 million shortly after the deal is finalized. The remaining $310 million is due by March 2028. The settlement is reportedly contingent on the pending sale of Omnicare to GenieRx Holdings.

Market Reaction and Analyst Outlook

The combination of a business-model-altering regulatory order and a significant cash outflow from the DOJ settlement created selling pressure, with the stock falling 1.7% in pre-open trading. The decline stood out in a modestly positive market, indicating it was a company-specific reaction.

Despite the near-term headwinds, some Wall Street analysts maintained a bullish long-term view. Truist Securities raised its price target on CVS to $118 from $108, while Wells Fargo recently lifted its target to $123 from $103. These actions suggest that some analysts believe the company's longer-term prospects remain intact even as it navigates these regulatory challenges.